CareDx beats by $0.44, beats on revs; raises FY24 revenue guidance above
consensus
- Reports Q1 (Mar) loss of $0.03 per share, $0.44 better than the FactSet Consensus of ($0.47); revenues fell 6.9% year/year to $72 mln vs the $63.13 mln FactSet Consensus.
- Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023.
- Co raises guidance for FY24, sees FY24 revs of $274-$282 mln vs. $266.97 mln FactSet Consensus
No comments:
Post a Comment